Analyst for Subu Nabi's questions to Myriad Genetics Inc (MYGN) leadership • Q1 2025
Question
An analyst from Guggenheim Securities asked for a breakdown of the Women's Health ASP increase between NIPT and carrier screening. They also inquired about progress with commercial payers on expanded carrier screening coverage and the potential ASP lift ahead of an anticipated ACOG guideline update.
Answer
CFO Scott Leffler confirmed a favorable rate environment for both NIPT and carrier screening but declined to provide a specific breakdown of the ASP contribution from each. He acknowledged incremental payer wins for expanded carrier screening but said the company is not yet quantifying the potential impact. CEO Samraat Raha reiterated that Myriad is prepared for the ACOG guideline update but has no new information on its timing.